Table 3.
Neuroimaging changes from baseline (adjusted) by group
| Neuroimaging changes | Double blind |
Open label |
AIBL Δ/yr | ||||
|---|---|---|---|---|---|---|---|
| 0–12 Mo |
12–24 Mo |
0–24 Mo |
|||||
| Placebo | PBT2 | Placebo | PBT2 | All | PBT2 | ||
| PiB SUVR Δ/yr (n) | −0.08 (15) | −0.09∗ (25) | −0.0034 (11) | 0.058 (16) | 0.033 (27) | −0.04 (16) | 0.06† (40) |
| FDG PCI SUVR Δ/yr (n) | −0.034∗ (15) | −0.041∗ (24) | −0.005 (11) | −0.002 (14) | −0.045‡ (25) | −0.046‡ (14) | N/A |
| Hippocampal volume Δ/yr (n) | −0.21† (15) | −0.11† (25) | −0.12∗ (11) | −0.27‡ (15) | −0.33‡ (26) | −0.18‡ (15) | −0.20† (30) |
| Gray matter volume Δ/yr | −4.15∗ | −5.86† | −0.62 | −7.50† | −4.58† | −5.92‡ | −7.22† |
| Ventricular volume Δ/yr | 2.80‡ | 3.15‡ | 3.07‡ | 3.22‡ | 3.16‡ | 2.76‡ | 3.81‡ |
Abbreviations: AIBL, Australian Imaging Biomarker and Lifestyle Study; PiB, Pittsburgh compound B; SUVR, standardized uptake volume ratio; FDQ, fluorodeoxyglucose; PCI, posterior cortical index; N/A, Not available.
∗
P < .05.
†
P < .001.
‡
P < .0001.